CyrionX Product Usage: This PRODUCT IS INTENDED FOR RESEARCH USE ONLY (RUO). Products are designed exclusively for laboratory and analytical research. All information on this website is for educational purposes only. Bodily introduction into humans or animals is strictly prohibited. Products must only be handled by qualified professionals. These products are not drugs, foods, or cosmetics.

BPC-157 & TB-500 Blend Topical

$119.99

Category:

BPC-157 + TB-500 Topical Research Formulation

BPC-157 + TB-500 Topical is a dual-peptide formulation developed for controlled laboratory investigation involving topical delivery systems, peptide stability, cellular signaling, and extracellular matrix models.

This formulation combines BPC-157 and TB-500–related peptide material within a topical research format, allowing investigators to evaluate their combined characteristics in qualified in vitro, ex vivo, and analytical models requiring surface-applied preparations.

Each batch is produced according to defined quality standards and supported by analytical documentation for identity, purity, and consistency.

PRODUCT INFORMATION

COMPOUNDS: BPC-157 + TB-500
CLASSIFICATION: DUAL-PEPTIDE RESEARCH FORMULATION
CAS NUMBER: MIXTURE — NO SINGLE CAS NUMBER
MOLECULAR FORMULA: MIXTURE
MOLECULAR WEIGHT: COMBINATION OF COMPONENTS
FORMAT: TOPICAL RESEARCH FORMULATION
APPEARANCE: MAY VARY ACCORDING TO FORMULATION

RESEARCH FOCUS

• TOPICAL PEPTIDE DELIVERY MODELS
• DUAL-PEPTIDE FORMULATION ANALYSIS
• PEPTIDE STABILITY AND COMPATIBILITY
• CELLULAR SIGNALING RESEARCH
• EXTRACELLULAR MATRIX MODELS
• IN VITRO AND EX VIVO EVALUATION

FOR RESEARCH USE ONLY

This product is intended strictly for controlled laboratory research and analytical purposes. It is not intended for human or veterinary use, personal skincare, consumption, diagnostic procedures, therapeutic applications, or the treatment or prevention of any disease.

Reviews

There are no reviews yet.

Be the first to review “BPC-157 & TB-500 Blend Topical”

Your email address will not be published. Required fields are marked *

Scroll to Top